Pristine Biologicals NZ opens serum manufacturing facility in Dargaville, New Zealand

The requirement for bovine serum from New Zealand for use in biologics manufacture has gone up many folds Pristine Biologicals NZ, a subsidiary of Indian Immunologicals Ltd (IIL), has inaugurated a new facility in Dargaville today for the production of sterile-filtered serum. The facility was inaugurated by Meenesh C Shah, Chairman of Indian Immunologicals and National Dairy Development Board, in the presence of Dr Jason Smith, the Mayor of Dargaville, Dr K Anand Kumar, MD, IIL, Dr Vijay Dasari, GM and Director, Pristine Biologicals (NZ) and many dignitaries. The requirement for bovine serum from New Zealand for use in biologics manufacture has gone up many folds and to meet the demands of the world markets, it is important to augment the capacities and also bring in more value-added products, the company feels. Many vaccine manufacturers in India have expressed difficulty in obtaining quality serum and have sought the help of IIL through the Government. In a recent visit to IIL, Hyderabad, Secretary DADF requested IIL to ramp up serum production capacity at Pristine NZ and also make it available to Indian companies on a priority basis. Speaking on the occasion of the plant expansion, Meenesh Shah, Chairman, Indian Immunologicals Ltd and National Dairy Development Board, “I am glad that an investment made overseas by Indian Immunologicals has come good. The affordable vaccines made in India required a sustainable supply of quality ingredients made by Pristine.” Speaking on the occasion Dr Anand Kumar (Managing Director) called Pristine a success story and said that plans are on the way to double the capacity soon as demands have gone up significantly. Dr Vijay Dasari (Director) thanked the Chairman and other Directors for the constant guidance and support for this venture.